RecruitingNot Applicable

Predictors of Poor Prognosis in HFpEF

Russia500 participantsStarted 2022-01-31

Plain-language summary

Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed and data informed consent;
✓. New York Heart Association (NYHA) class II-III heart failure;
✓. Left ventricular ejection fraction \> 50%;
✓. Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.

Exclusion criteria

✕. Evidence of myocardial ischemia during stress echocardiography;
✕. Significant lesions of the main coronary arteries;
✕. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
✕. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
✕. Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);
✕. Primary pulmonary artery hypertension;
✕. Significant left-sided structural valve disease;
✕. Anemia (Hb \< 100 g/L);

What they're measuring

Hospitalization for exacerbation of HF

Timeframe: From enrollment to August 2026

All-cause mortality

Timeframe: From enrollment to August 2026

Trial details

NCT IDNCT06844032

SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Artem G Ovchinnikov, MD, PhD, DSc

+74954146612 artcardio@mail.ru

View on ClinicalTrials.gov More HFpEF trials